key: cord-0811085-tibuk0nt authors: Norderfeldt, Joakim; Liliequist, Andreas; Frostell, Claes; Adding, Christofer; Agvald, Per; Eriksson, Maria; Lönnqvist, Per‐Arne title: Acute pulmonary hypertension and short‐term outcomes in severe Covid‐19 patients needing intensive care date: 2021-03-27 journal: Acta Anaesthesiol Scand DOI: 10.1111/aas.13819 sha: 03f24b008a5713deef4c94c22c817d1c761f45a9 doc_id: 811085 cord_uid: tibuk0nt INTRODUCTION: Critically ill Covid‐19 pneumonia patients are likely to develop the sequence of acute pulmonary hypertension, right ventricular (RV) strain, and eventually RV failure due to known pathophysiology (endothelial inflammation plus thrombo‐embolism) that promotes increased pulmonary vascular resistance and pulmonary artery pressure. This study aimed to investigate the occurrence of acute pulmonary hypertension (aPH) as per established trans‐thoracic echocardiography (TTE) criteria in Covid‐19 patients receiving intensive care and to explore whether short‐term outcomes are affected by the presence of aPH. METHODS: Medical records were reviewed for patients treated in the intensive care units at a tertiary university hospital over a month. The presence of aPH on the TTE was noted, and plasma NTproBNP and troponin were measured as markers of cardiac failure and myocardial injury, respectively. Follow‐up data were collected 21 d after the performance of TTE. RESULTS: In total, 26 of 67 patients (39%) had an assessed systolic pulmonary artery pressure of > 35 mmHg (group aPH), meeting the TTE definition of aPH. NTproBNP levels (median [range]: 1430 [102‐30 300] vs. 470 [45‐29 600] ng L(−1); P = .0007), troponin T levels (63 [22‐352] vs. 15 [5‐407] ng L(−1); P = .0002), and the 21‐d mortality rate (46% vs. 7%; P < .001) were substantially higher in patients with aPH compared to patients not meeting aPH criteria. CONCLUSION: TTE‐defined acute pulmonary hypertension was frequently observed in severely ill Covid‐19 patients. Furthermore, aPH was linked to biomarker‐defined myocardial injury and cardiac failure, as well as an almost sevenfold increase in 21‐d mortality. The pathophysiologic mechanisms associated with severe Covid-19 pneumonia promote the sequence of acute pulmonary hypertension (aPH), right ventricular strain (RVS) and right ventricular failure (RVF) . First, the disease process produces generalized inflammation of the endothelium ('endothelitis'), including the microvasculature of the pulmonary circulation. 1, 2 Consequently, the production of the vasodilators nitric oxide and prostacyclin by the endothelium is reduced, promoting vasoconstriction of the pulmonary vessels. Second, Covid-19 is associated with coagulopathy that causes microembolization and macroembolization in the pulmonary circulation, 3 further increasing the risk of aPH. Coagulopathy combined with the reduced antiplatelet action of nitric oxide and prostacyclin will prompt in situ thrombosis of microvessels in the pulmonary vasculature, 2 which rarely occurs in association with more typical ICU diseases. These factors set the stage for the development of aPH and associated problems. Despite the occasional publication linking severe Covid-19 infection to the development of acute core pulmonale, 4 there has been remarkably little information published regarding the sequence of aPH, RVS and RVF. For example, a recent comprehensive review article on the cardiovascular aspects of Covid-19 failed to mention aPH as an important pathophysiologic issue. 5 Thus, the primary aim of the present retrospective observational study was to determine how frequently aPH occurs in severe Covid-19 infection and to assess whether aPH is associated with a worse short-term outcome (mortality). Secondary outcomes included left ventricular ejection fraction (LVEF), plasma D-dimer (a proxy for the degree of coagulopathy), NTproBNP (a proxy for cardiac failure) and troponin T (a proxy for myocardial injury), as well as the composite outcome measure of death or still in need of mechanical ventilation at 3 weeks after TTE. This study was approved by the National Swedish Ethics Committee (Dnr 2020-02250; Chairperson Gunilla Robertsson), which waived the need for patient consent, and an amendment (Dnr 2020-03428). It was performed and reported under the STROBE guidelines for cohort studies. The study was registered at ClinicalTrials. gov (NCT04459364). A flowchart of the study process is provided in Figure 1 . Ongoing veno-arterial extracorporeal membrane oxygenation was also an exclusion criterion due to the completely altered pulmonary circulation that occurs with this treatment modality. Patient-related information was extracted from each patient's electronic medical record file. Per the study protocol, the outcome data for all included patients were analysed 21 days after the performance of the TTE. The outcomes were classified as (1) dead, (2) still on mechanical ventilation in the ICU, or (3) alive without the need for mechanical ventilation. Based on previous publications and the data routinely recorded by the Swedish Intensive Care Registry (SIR), 6 the following parameters were considered risk factors in association with Covid-19: age over 70 y, hypertension, cardiopulmonary disease, renal disease, obesity, diabetes mellitus, and immunosuppression. Per the hospital ICU care Covid-19 protocol for the period of the study, all patients received prophylactic anticoagulation by lowmolecular-weight heparin at 50-75 IU kg −1 twice daily or intravenous heparin (to an APTT target of 70-90 s) for those with verified thrombo-embolism. All TTE examinations were performed by one experienced physician, certified in echocardiography, using a Vivid S70 or a Vivid IQ Patients without TR or patients with an estimated sPAP ≤ 35 mmHg and no RV dysfunction have a low echocardiographic probability of PAH and were classified as a non-aPH group. 11 The estimation of RA pressure was performed in the subcostal view by measuring the diameter of the inferior vena cava and recording its respiratory changes. 8 Values for D-dimer (mg L −1 , fibrinogen equivalent units [FEU], fibrin degradation products; turbidimetry; decision limit, age dependent: 0.01 × age [years]) as a marker of deep venous thrombosis/pulmonary embolism, NTproBNP (ng L −1 ; prohormone of brain natriuretic peptide; electrochemiluminescence; reference interval: women, <222; men, <194) as a marker of cardiac failure, and troponin T (ng L −1 ; electrochemiluminescence; reference interval: <15) as a marker of myocardial injury were taken from the same day as the TTE, forming an additional part of the daily clinical routine. All laboratory analyses were performed at the Karolinska University Hospital Laboratory. Since this was a purely exploratory observational study, no formal power calculation was performed, mainly because no previous data exist regarding Covid-19 and central hemodynamics. The primary aim of the study was twofold. First, the goal of this exploratory observational study was to determine the presence of aPH based on described TTE criteria and to investigate if the presence of aPH affected mortality in ICU-treated Covid-19 patients. The follow-up data were collected 21 d after the performance of TTE. Prior to the study, we decided to compare the outcome of dead vs. alive for aPH patients vs. non-aPH patients. Thus, 30-d mortality following the admission to ICU was also assessed. Another aim was to investigate the correlation between the various patient-related factors (Table 1) with severe Covid-19 disease. In particular, the relationship between aPH and the plasma levels of D-dimer, NTproBNP, troponin T and LVEF was identified for exploration. A further 21-d post-TTE outcome analysis was also performed based on a worse (dead or still on mechanical ventilation) or a better (still in the ICU but not requiring mechanical ventilation, discharged to a regular ward or discharged home) outcome between patients with or without aPH as determined by TTE. Since a Gaussian distribution could not be expected, the data were presented and analysed using a non-parametric approach. Data are presented as median and range. Chi-square analysis with Yates' correction (outcome) or a Mann-Whitney U test (D-dimer, NTproBNP, troponin, and LVEF) was used for comparison between groups; P values < 0.05 were considered statistically significant. Table 1 . Data related to group non-aPH and group aPH are also shown in Table 1 . The mode of ventilatory support and ventilatory settings are summarized in Table 2. TTE parameters for the aPH and non-aPH groups are shown in Table 3 . The time between ICU admittance and the TTE was 8 (1-28) days. In total, 26 patients (39%) displayed a sPAP value of > 35 mmHg and were designated as having aPH; 33 patients either had no TR or such a small TR that the assessment of sPAP was not possible. Eight patients had a TR that allowed the estimation of sPAP but did not demonstrate sPAP values exceeding 35 mmHg. Thus, the non-aPH group consisted of 41 patients in total (Table 1) . At the 21-d follow-up, a greater proportion of patients (n = 12) in the aPH group had died compared to patients (n = 3) in the non-aPH group (46% vs. 7%, respectively; P < .001; see Figure 2 ). Also, 30-d mortality following admission to ICU care follow-up showed a higher mortality rate in the aPH group (n = 11) as compared to non-aPH group (n = 3; 42% vs. 7%, respectively; P < .002). The patient in group aPH who differed between the 21-d follow-up and the 30-d ICU mortality died on ICU day 31. vs. 15 ng L −1 , P = .0002, respectively), as noted in Table 1 and The main finding of this study was that approximately 40% of Moreover, it has been speculated that aPH, with associated negative effects on the right ventricle, may be both underdiagnosed and underestimated as a reason for the deterioration and death of patients with regular ALI/ARDS. In fact, previous studies have shown that the presence of aPH is an independent risk factor for poor outcomes in ICU care. 13, 14 Typical ALI/ARDS is known to be associated with pulmonary vascular inflammation and pulmonary microembolism. 15 The results of this study show that aPH, when diagnosed by TTE criteria as an sPAP > 35 mmHg, 12 Note the y-axis in panel B is logarithmic a worse short-term outcome (mortality rate of 46%) than patients without aPH (mortality rate of 7%, see Figure 2 ). However, both studies identify that an sPAP above 35 mmHg appears to be associated with a poorer outcome, even though we did not observe any significant decrease in TAPSE in the aPH group in our study (Table 3 ). A striking overrepresentation of males was observed in the ICU cohort, which reflects findings from previous publications. Regarding age, the presence of one or more risk factors, and days of symptoms prior to hospital admission, our data did not diverge from the SIR results. 6 There was no difference between the aPH and non-aPH groups with regard to biomarkers for thrombo-embolism (D-dimer) or LVEF. The lack of difference between D-dimer values among the two groups is somewhat surprising since it could be assumed that patients in the aPH group would have a greater problem with thrombo-embolization than the non-aPH group, thereby at least partly explaining the difference in sPAP. This lack of difference could be due to the following finding: both groups had a similar thromboembolism burden, but the blood clots in the non-aPH group were fixed in the peripheral veins, whereas a certain amount of blood clots had detached and embolized the pulmonary circulation in the aPH group, thereby producing increased sPAP. Alternatively, perhaps the aPH patients had more severe 'endothelitis' of the pulmonary micro-vessels, thereby creating a more pronounced spastic component of pulmonary vascular resistance than the non-aPH group. In contrast, the biomarkers of cardiac failure (NTproBNP 18 and myocardial injury (troponin T) 19 were higher in the aPH group as compared to non-aPH patients. Our observation that few patients were judged to need inotropic support, paired with a well-preserved LVEF on TTE ( Table 1 ), indicated that NTproBNP and troponin release likely stems from a strained or failing right ventricle. Determining the presence of aPH by echocardiography poses cer- The authors would like to thank Senior Professor Göran Hedenstierna for providing a critical review of the manuscript and Senior Professor Staffan Eksborg for assistance with Mann-Whitney U statistics and figure production. We also want to thank Professor Edide Weitzberg for help with data retrieval. This study was supported by the Swedish Research Council (2015-02880) and an unrestricted educational grant from Attgeno AB. JN performed all TTE, TTE data handling and analysis and contribution to and review of the manuscript. AL supported JN during the performance of TTE and reviewed the manuscript. CF contribution to study design and ethics application. Data retrieval and manuscript text and review. CA contributed to study design and ethics application and data retrieval and manuscript review. PA contributed to study design and ethics application and data retrieval and manuscript review. ME performed TTE data handling and analysis and contribution to and review of manuscript. PAL. performed the primary investigation and contribution to study design and ethics application, data retrieval, data analysis, and manuscript text and review. Claes Frostell https://orcid.org/0000-0002-7199-1310 Per-Arne Lönnqvist https://orcid.org/0000-0002-8586-1429 Endothelial cell infection and endothelitis in COVID-19 Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Acute cor pulmonale in critically Ill patients with Covid-19 COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options Swedish Intensive Care Registry Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging State-of-the-art review: echocardiography in pulmonary hypertension Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT) Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19 Doppler-defined pulmonary hypertension in medical intensive care unit patients: Retrospective investigation of risk factors and impact on mortality Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome The pulmonary vascular lesions of the adult respiratory distress syndrome Pulmonary vasculopathy in acute respiratory distress syndrome: something new, something old Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting Myocardial injury in the era of high-sensitivity cardiac troponin assays: a practical approach for clinicians Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care